EX-10.4



 Exhibit 10.4 

AGREEMENT 
 This Agreement
(“Agreement”) is made and entered into as of the 3 day of February 2013 (“Effective Date”), by and between: 
 Tel
Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives
(“THM”); and 
 Prof. Dror Harats, ID no. 054496641 of Ramat Gan, Israel (“Prof. Harats”); and

 Vascular Biogenics Ltd., Company no. 51-289976-6, a private company duly incorporated under the laws of the State of Israel having its
registered office at 6 Yoni Netanyahu Street, Or Yehuda, Israel, 60376, represented by its authorized representatives (“VBL” or the “Company”). 

 

	WHEREAS:	THM declares that it is a private company, whose purpose is to promote the welfare of the Sheba Medical Center (the “Hospital”); and 


 

	WHEREAS:	THM declares that at the request of the Hospital and the Fund, as defined below, THM undertook to act as the operational body of the Hospital and Fund, with respect to promotion, development and commercialization
of intellectual property deriving from inventions of Hospital’s and/or Fund’s employees;and 

  

	WHEREAS:	Prof. Harats has been an employee of the Hospital and/or the Fund since 1995; and 

  

	WHEREAS:	VBL was established in 1999; and 

  

	WHEREAS:	The Hospital and the Fund have claims regarding the ownership of certain inventions and patent rights of the Company, developed in part by Prof. Harats, and certain other inventors defined herein as Inventors and VBL
disagrees, denies and refutes all such claims in their entirety; and 

  

	WHEREAS:	THM, on behalf of the Hospital, and the Fund reached an agreement resolving the above dispute as stipulated and set forth hereunder; 


  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 NOW, THEREFORE, in consideration of the mutual covenants and undertakings herein contained, the parties
hereby agree and stipulate as follows: 
  

	1.	PREAMBLE AND DEFINITIONS 

  

	 	1.1	The Preamble to this Agreement as well as all the Agreement’s appendices constitutes an integral part thereof. 

  

	 	1.2	The descriptive headings of this Agreement are inserted for convenience only and shall not be considered a part or affect the interpretation of this Agreement. 


 

	 	1.3	In addition to terms defined elsewhere in this Agreement or its appendices, the following terms shall have the meaning ascribed to them hereinafter: 


 

	 	1.3.1	“Affiliate” shall mean, with respect to a Party, any person, organization or entity controlling, controlled by or under common control with, such party. For purposes of this definition only,
“control” of another person, organization or entity shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the activities, management or policies of such person, organization or entity, whether
through the ownership of voting securities, by contract or otherwise. Without limiting the foregoing, “control” shall be presumed to exist when a person, organization or entity (i) owns or directly controls fifty percent (50%) or
more of the outstanding share capital or other ownership interest of the other organization or entity, or (ii) possesses, directly or indirectly, the power to elect or appoint fifty percent (50%) or more of the members of the governing
body of the organization or other entity. 

  

	 	1.3.2	The “Fund” shall mean Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical Center (RA). 


 

	 	1.3.3	“Intellectual Property” shall mean any or all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including without limitation: (i) all United States,
Israeli, international and foreign patents and applications therefor (including PCT), including any and all reissues, divisionals, patent of division applications, renewals, extensions, continuations, and continuity applications thereof, whether or
not related to such divisionals, patent of division application, renewals, extensions, continuations or continuity applications through one or more intervening applications, and any patent or application acquired as a result of prevailing in any
interference proceeding (the “Patent Rights”); (ii) all inventions (whether patentable or not), invention disclosures, trade secrets, proprietary information, know-how, technology, technical data and customer lists, and all
documentation in any form or media relating to any of the foregoing; (iii) all copyrights, copyrights registrations and applications therefor, and all other rights corresponding thereto throughout the world; (iv) all databases and data
collections and all rights therein throughout the world; (v) all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications therefore throughout the world; and (vi) all domain
names, uniform resource locators, and other names and locators associated with the internet. 


  
 2 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	1.3.4	The “Inventors” – As specifically detailed in Appendix A attached hereto and constituting an integral part thereof. Such Inventors are inventors who have been employed by Sheba.


  

	 	1.3.5	The “Company’s IP”: shall mean (i) the Intellectual Property owned, registered or controlled by the Company which is specified in Appendix B attached hereto; (ii)any
continuations in part of the Company’s IP listed in Appendix B; and (iii) any Intellectual Property to the extent that it is dated prior to the date hereof and incorporates and /or based upon the patents specified in
Appendix B and/or any Intellectual Property to the extent that it is dated prior to the date hereof and that the patents listed in Appendix B are based thereon. 

  

	 	1.3.6	The “Products” shall mean any product, agent, process, or service device which is covered by or is produced or manufactured or rendered (as the case may be) using a process or method covered by the
Company’s IP. 

  

	 	1.3.7	“Net Sales” shall mean the total amount invoiced by or on behalf of VBL or any of its Affiliates or Licensees, in connection with the sale of a Product after deduction of: (i) value added taxes,
excise and sales taxes, or other similar taxes imposed on such sales (excluding income or franchise taxes of any kind) (ii) amounts credited by a credit note; and (iii) reasonable quantities for promotional purposes, and compassionate
uses; provided however that the Company doesn’t receive any consideration relating thereto; 

  

	 	  	For the purpose hereof: (a) with respect to sales which are not at arm’s length and/or are not according to the current market conditions for such a sale, the term “Net Sales” shall mean the total
amount that would have been paid in an arm’s length sale made according to the current market conditions for such sale or according to market conditions for sale of products similar to the Products; (b) with respect to sales by VBL and/or
a Licensee, as applicable, to any Affiliate, the term, “Net Sales” shall mean the higher of: (i) “Net Sales”, as defined above in paragraph (a) and (ii) the total amount invoiced by such affiliated entity on resale
to an independent third party purchaser and (c) with respect to sales for non-monetary consideration for any Products, “Net Sales” shall be calculated based on the higher of: (i) “Net Sales”, as defined in paragraph
(a) above; and (ii) the total amount invoiced by the party acquiring the Products in such transaction in each case, after deducting the amounts permitted above, to the extent applicable. 


 

	 	1.3.8	“License” shall mean the grant of any right or license and any agreement executed, by VBL to or with any entity, permitting any use of Company’s IP (or any part thereof) including for the
development and/or manufacture and/or marketing and/or distribution and/or sale of Company’s IP, and/or the Products and the term “Licensee” shall be construed accordingly. 


  
 3 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	1.3.9	“License Fee” shall mean the consideration of any type or nature, received (for the removal of doubt, whether received before or after the First Commercial Sale in any country) by the Company in return
for or in connection with the grant of Licences or the grant of an option for a Licence, and excluding amounts received by the Company which are included under the definition of “Net Sales” based on sales of the Products by Licensees, in
respect of which the Company has paid royalties to THM according to this Agreement or otherwise constitute payment upon Exit Event according to this Agreement; License Fee shall include any lump sums, revenues from License Fees, milestone payments,
etc. but shall specifically exclude reimbursement for research and development and patent related expenses/reimbursement for payments specifically committed to cover costs reasonably and actually incurred by Company under, and in accordance with
detailed budgets and workplans included in, license agreements with Licensees. Any consideration other than cash payment shall be calculated based on the fair market value of such consideration assuming an arm’s length transaction made in the
ordinary course of business. Upon request, the Company shall provide THM with all documents and figures reasonably necessary in order to verify Company’s compliance with this clause. 


 

	 	1.3.10	“First Commercial Sale” shall mean with respect to any Product in any country, the first commercial sale of the Product in such country after FDA Approval for marketing or equivalent approval in such
country has been obtained if such approval is required. 

  

	2.	PARTIES’ DECLARATIONS AND UNDERTAKINGS 

  

	 	2.1	THM undertakes and covenants as follows: 

  

	 	2.1.1	Subject to the performance of the Company’s obligations hereunder, THM hereby irrevocably confirms on behalf of the Hospital and the Fund that such entities, or anyone on their behalf do not have any further right
to receive any payment, compensation, funds or securities from Prof. Dror Harats and/or from the Company (including its officers, directors, shareholders, employees, affiliates, successors and assigns, whether current, past or in the future) and/or
the Inventors (the “Released Parties”) deriving from any claim of ownership in the Company’s IP, and hereby irrevocably waives and releases acquits and forever discharges each of the Released Parties from any and all rights,
claims, demands, commitments, actions, charges, complaints, promises, agreements, controversies, debts, counterclaims, suits, causes of action, damages, liabilities, obligations, costs and expenses of every kind and nature whatsoever, known or
unknown, past, present or future, at law or in equity, contingent or otherwise (collectively, a “Claim”), such parties, including their successors and/or assigns, may have, as a result of a claim of ownership in the Company’s
IP now or in the future, (“Released Matters”). 


  
 4 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	    	Notwithstanding anything to the contrary in this Agreement, it is hereby clarified that the above waiver specified in this clause 2.1.1, applies and relates only to any part of the Company’s IP which is created,
conceived and/or developed by the Inventors and not to Company’s IP or any part thereof or any other Intellectual Property owned by the Company which is created, conceived and/or developed by any other inventors, employees, agents and/or
contractors on behalf of the Company to the extent they are not listed in Appendix A. 

  

	 	2.1.2	2.1.3 Prof Harats shall be entitled to serve as Chief Executive Officer and member of the Board of Directors of the Company to develop intellectual property that constitutes continuations in part of the Company IP and
subject to duly filing the required reports to THM and to the Ministry of Health, to receive compensation in shares and in cash, without any further claim by the Releasing Parties. 


 

	 	2.2	Each party hereby represents and warrants that: (a) it has the power and authority to execute and deliver this Agreement, and to perform its obligations hereunder, and that the execution, delivery and performance
by it of this Agreement and its compliance with the terms and provisions hereof do not and will not conflict with or result in a breach of any of the terms and provisions of or constitute a default under (i) any loan agreement, guaranty,
financing agreement, agreement affecting a product or other agreement or instrument binding or affecting it or its property; (ii) any other right or obligation provided under any other agreement or obligation that it has with any third party;
or (iii) any order, writ, injunction or decree of any court or governmental authority entered against it or by which any of its property is bound; (b) the Agreement is a binding enforceable obligation of such Party; and (c) no
consent, approval, authorization order, filing, registration, or qualification of or with any court, governmental authority, or third person is required to be made or obtained by a party in connection with the execution and delivery of this
Agreement or the consummation by a party of the transactions contemplated hereby, which has not been received. 


  
 5 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	3.	LICENSE BY THE COMPANY 

 VBL undertakes that any License granted by it shall be subject to the
following terms: 
  

	 	3.1	The License is granted according to a written appropriate and binding agreement. The material terms of each License will be disclosed orally by the legal counsel of VBL to the head of THM prior to the execution of any
License agreement. Following execution of any such agreement, the Company will either (i) provide a copy of such agreement to THM; or (ii) if the provision of a copy of such agreement is not allowed under the terms thereof, disclose to
THM’s attorney and its accounting firm the material terms of such agreement, including without limitation, any terms that have bearing upon the consideration payable to THM hereunder. Such disclosure to THM’s attorney or CPA shall be
subject to their execution of a non disclosure agreement. The Company shall verify that the License includes terms that will allow the disclosure of the material terms thereof to THM or to a third party to be designated by THM, and shall comply with
such terms. 

  

	 	3.2	The License is being granted in a bona fide arms-length commercial transaction. 

  

	 	3.3	Non monetary consideration, if any, shall be valued as set forth in this Agreement. 

  

	4.	CONSIDERATION TO THM 

  

	 	4.1	VBL undertakes to pay THM the following amounts on a Product-by-Product and country-by-country basis until the later to occur of: (i) the last to expire or terminate of any of the Patent Rights covering such
Product in such country; or (ii) fifteen (15) years from the date of the First Commercial Sale of such Product in such country: 

  

	 	4.1.1	Royalties. VBL shall pay THM 1% (one percent) of Net Sales by or on behalf of VBL or any Affiliate or any Licensee (the “Royalties”). 


 

	 	4.1.2	Licensing Consideration. VBL shall pay THM 2% (two percent) of any License Fee received by VBL (the “Licensing Consideration”). 


 

	 	4.2	The amounts payable to THM under clause 4.1 shall be paid as follows: 

  

	 	4.2.1	Royalties, as specified in sub-clause 4.1.1 in connection with Net Sales by VBL and its Affiliate, shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which the respective sale
took place, commencing on the first quarter where the First Commercial Sale took place. Royalties in connection with Net Sales by a Licensee shall be paid on a quarterly basis, within 60 (sixty) days after the end of each quarter in which VBL
receives payment on account of Net Sales. 

  

	 	4.2.2	Licensing Consideration, as specified in sub-clause 4.1.2 shall be paid within 30 (thirty) business days from receipt of any License Fee by the VBL. 


  
 6 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	4.3	Consideration from Exit. Upon the closing of each Exit Event, as defined bellow, THM shall be entitled to receive from the Company 1% (one percent) of any and all consideration received by the Company and/or its
shareholders as a result of or in connection with such Exit Event (“Consideration From Exit”). 

 Consideration from Exit
Event under clause 4.3 shall be paid in cash within 15 (fifteen) days from the closing of the Exit Events defined above. To the extent that the applicable Exit Event is an IPO or the consideration is in kind and not cash payment then the Company may
pay the Consideration From Exit within 12 months following the closing of the respective Exit Event. 
 “Exit Event” means any of the
following events: (i) the closing of the merger or consolidation of VBL into or with other corporation or the acquisition of the Company thereby, excluding a transaction following which VBL is the surviving corporation and the shareholders of
VBL prior to the transaction constitute the majority of the shareholders following such transaction; or (ii) the closing of the sale of all or substantially all of the assets of VBL or all or substantially all of its issued and outstanding
share capital or (iii) the closing of an Initial Public Offering (“IPO”). Notwithstanding the above, in all cases, a transaction with a wholly owned subsidiary or a transaction effected for the purpose of changing the domicile
or structure of VBL shall not be deemed an Exit Event. 
  

	 	4.4.	Payment obligations under clause 4 shall expire if the payment to THM upon or prior to such Exit Event (but not by way of payment of Royalties under clause 4.1.1) is or exceeds NIS100 million. In addition, at any time
following the execution hereof the Company, its assignees or successors shall be entitled to terminate the payment obligations under clause 4 by payment to THM of the amount of NIS100 million after deduction of any amount previously received by THM,
provided that such amounts were not received by THM as Royalties under clause 4.1.1. It is hereby clarified that termination of the obligation to pay Consideration From Exit, according to this clause 4.4 which did not exceed NIS 100 million,
does not and shall not derogate from Company’s obligation for payments as specified in clauses 4.1.1 and 4.1.2 until an aggregate payment of NIS 100 million has been made (but not by way of payment of Royalties payable under clause 4.1.1).


  

	 	4.5	All amounts set forth herein are inclusive of any and all taxes. The Company (or the escrow agent, if applicable) shall be entitled to deduct at source or withhold from any amount payable hereunder any tax amount
applicable to THM in connection with each payment. 

  

	 	4.6	The Company shall report in writing to THM immediately upon execution of an agreement relating to the First Commercial Sale and upon the occurrence of such first Commercial Sale. The Company shall specify in such report
the date of execution of such agreement and the date of the First Commercial Sale according to the agreement. 

  

	 	4.7	In calculating Net Sales and License Fee, all amounts shall be expressed in US Dollars and any amount received or invoiced in a currency other than US Dollars shall be translated into US Dollars, for the
purposes of calculation, in accordance with the exchange rate between the US Dollar and such currency on the date of such receipt or invoice, as the case may be. 


  
 7 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	4.8	The Company shall provide THM with the following written reports: (a) a detailed quarterly report, commencing with the first calendar quarter in which any Net Sales are made, or License Fee received, in a form
reasonably acceptable to THM, signed by the chief financial officer of VBL, specifying all amounts payable to THM under this clause 4 in respect of the previous quarter to which the report refers. Such report shall include: (i) the sales made
by the Company, Affiliates and Licensees with a breakdown of Net Sales according to country, identity of seller, currency of sales, dates of invoices, number and type of Products sold and; (ii) License Fee with a breakdown according to identity
of Licensees, countries, the currency of the payment and date of receipt thereof; and (iii) deductions applicable, as provided in the definition of “Net Sales”; (b) a detailed report within twenty one (21) days of an Exit
Event specifying the nature of the Exit Event, the consideration to be received by the Company or its shareholders in connection with such Exit Event and all other substantial terms and details of such Exit Event and enclose to the report any
agreement executed in connection with such Exit Event immediately following the execution thereof; and (iv) any other matter, data and documents reasonably required by THM and existing with VBL in order to calculate and/or verify the amounts
payable hereunder; and (c)Within four months after the end of each fiscal year, the Company will provide THM with a detailed report, certified by VBL’s Chairman of the Board and by its independent auditor, stating all amounts due to THM
pursuant to this clause 4 in the reported year including relevant invoices issued and all invoices and all payments received by the Company with respect to details specified in the above reports; 21 days prior to an Exit Event he material terms of
such Exit will be disclosed orally by the legal counsel of VBL to the head of THM. 

  

	 	4.9	The Company shall keep and shall cause Licensees to keep complete, accurate and correct books of account and records consistent with sound business and accounting principles and practices. 


 

	 	4.10	Following the First Commercial Sale, THM shall be entitled to appoint an independent auditor selected by it to inspect, after coordination with VBL and during VBL’s regular business hours, all records, and
documents of VBL as may contain information bearing upon the amounts payable to THM under this clause 4. The Company shall take all steps necessary so that all such books of account, records and other documentation of VBL and its Licensees and
Affiliates are available for inspection as aforesaid for each of the Company and its Licensees and Affiliates. The cost of such auditing shall be borne by VBL if the audit uncovers an underreporting of the corresponding amounts owed to THM by more
than ten percent (10%). Otherwise, such costs and expenses shall be borne by THM. VBL shall remedy such discrepancy and pay (i) the shortfall within thirty (30) days of the date of discovery; and (ii) interest thereon at the rate of
4% above the London Interbank Offered Rate (LIBOR) applicable to a 12 month USD deposit, as such rate shall be in effect on each Disbursement Date. The Interest shall be compounded annually and computed on the basis of a 360 day year.



  
 8 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	4.11	Upon THM’s request but not more than once every six months, the Company shall provide THM with a progress report specifying the following details, as updated from the last report: (i) the activities the
Company conducted for the development of Products; and (ii) sales and marketing efforts. 

  

	5.	INDEMNITY 

  

	 	5.1	VBL undertakes to indemnify and hold harmless THM, the Fund, the Hospital, the State of Israel, and their employees, representatives, agents and contractors (the “THM Beneficiaries”) against and from
any loss, liability, claims, damages or expenses of whatever kind or nature incurred by or imposed upon the THM Beneficiaries, to the extent arising out of or resulting from (i) the use and/or exploitation of the Company’s IP or any use of
any products incorporating the Company’s IP or any part thereof and/or manufactured or developed based upon the Company’s IP; and (ii) to the extent that it is based on a claim that the Company’s IP, the Products or other
material produced or developed or marketed by or on behalf of VBL or any of its Affiliates or Licensee infringes any third party’s intellectual property rights including copyright, trade secret, patent, trademark (a “THM
Claim”). 

  

	 	5.2	     

  

	 	5.3	The following mechanism shall apply to any THM Claim pursuant to clause 5.1. If any THM Beneficiary receives notice of any THM Claim, such THM Beneficiary shall, as promptly as is reasonably
possible, give VBL notice of such THM Claim. The failure to give such notice promptly shall relieve VBL of any indemnification obligation it may have hereunder to the extent such failure diminishes its ability to respond to or to defend the
Beneficiary against such THM Claim. VBL shall exclusively assume the defence or represent the interests of the THM Beneficiary in respect of such THM Claim, that shall include the right to select and direct legal counsel and other
consultants to appear in proceedings on behalf of the THM Beneficiary and to propose, accept or reject offers of settlement, all at its sole cost and discretion. 

  


	 	5.4	VBL, at its own expense, shall maintain insurance in an amount consistent with industry standards which provides VBL adequate coverage for (i) performing clinical studies of the Product in humans, (ii) product
liability and (iii) commercial sales of applicable and relevant Products. 

  

	6.	PATENT RIGHTS 

 In the event that the Company decides to abandon its patents in all
applicable jurisdictions in connection with its intent to stop its entire business activities of either of its two business units, then with respect to such Patent Rights that are included in the Company’s IP, the Company will inform THM
(“VBL Notice”) of its intention prior to the abandonment of any such Patent Rights. 

  
 9 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 THM shall have the right to continue to support and maintain any such Patent Rights provided that it notifies VBL
of its intention within 30 days following the receipt of VBL Notice, and provided further that within 60 days following the notice by THM, the parties reach an agreement for the assignment or license of such Patent Rights to THM. The parties shall
negotiate such agreement in good faith. The parties further agree that such agreement shall provide VBL with payments similar to those set forth in clause 4 and that any such agreement shall be subject to any limitations and restrictions imposed by
applicable third parties, including without limitation, the Office of the Chief Scientist and shall be subject to the assumption by THM of any repayment obligations thereto. THM right hereunder shall lapse and be of no further force and effect, in
the event that THM fails to timely respond to VBL Notice, indicates that it is not interested in the Patent Rights or otherwise the parties fail to reach an agreement as aforesaid during the 90 day period. 

 

	7.	MISCELLANEOUS  

  

	 	7.1	Law and Venue. All disputes arising in connection with this Agreement shall be settled amicably in the first instance. If amicable settlement cannot be reached by the Parties within 15 (fifteen) days from the day
either Party approached the other Parties specifying the essence of the dispute, the dispute shall be settled by 1 (one) arbitrator. If the Parties fail to reach an agreement on the nomination of the arbitrator within 30 (thirty) days of the date
when the claimant’s request for arbitration was communicated by the other Parties, the appointment shall be made by the Head of the Israel Bar. The arbitration will be conducted in Tel Aviv, Israel. The Parties shall be entitled to seek interim
measures of protection in the form of pre-award attachment of assets or injunctive relief. The tribunal shall issue a reasoned award. Such award may grant any relief appropriate under applicable law including without limitation declaratory relief
and/or specific performance. As part of its award the tribunal may award attorneys fees and costs to the prevailing party. The award of the arbitrator shall be final and binding upon the Parties, but subject to appeal, with respect to the disputes
so submitted and the costs of such arbitration. The law that shall apply shall be the statutes and laws of the State of Israel. 

  

	 	7.2	Use of Names. The Company shall not use the names of the State Of Israel, Hospital, the Fund and/or THM and/or their employees, representatives, agents and contractors in any manner or in any publication
including commercial publicity, without the prior written consent of THM. 

  

	 	7.3	Assignment. This Agreement shall be personal to the parties and therefore the Parties may not assign any of their rights or obligations hereunder without the prior written consent of the other party.
Notwithstanding the aforementioned, THM shall be entitled to assign the right to receive payments under this Agreement to any association and/or organization and or company that was established in connection with or for the benefit of the Hospital.
In addition, VBL may, without the consent of THM, assign this Agreement and the rights, obligations and interests of VBL, in whole, to any purchaser of all or substantially all of its assets, or to any successor corporation resulting from any merger
or consolidation of VBL with or into such corporation, provided that any such assignee agrees in writing to be bound by all the terms of this Agreement. 


  
 10 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










	 	7.4	Notices. Except as otherwise provided in this Agreement, all notices permitted or required by this Agreement shall be in writing and shall be deemed to have been duly served (i) upon personal delivery
(ii) upon facsimile transmission (receipt of which has been orally confirmed by the recipient) or (iii) Seven (7) business days after deposit, postage prepaid, return receipt requested, if sent by Registered Mail and addressed to the
address of the parties first above stated or in accordance with such other address information as the party to receive notice may provide in writing to the other party in accordance with the above notice provisions. Any notice given by any other
method will be deemed to have been duly served upon receipt thereof. 

  

	 	7.5	Waivers. No course of dealing in respect of, nor any omission or delay in the exercise of, any right, power, or privilege by either Party shall operate as a waiver thereof, nor shall any single or partial
exercise thereof preclude any further or other exercise thereof or of any other, as each such right, power, or privilege may be exercised either independently or concurrently with others and as often and in such order as each party may deem
expedient. 

  

	 	7.6	Entire Agreement; Amendments. This Agreement, including, without limitation, its schedules, contains the entire agreement of the parties with respect to its subject matter. No oral or prior written statements or
representations not incorporated herein shall have any force or effect, nor shall any part of this Agreement be amended, supplemented, waived or otherwise modified except in a writing signed by both parties. 


 

	 	7.7	Confidentiality. Each party undertakes to the other party that all confidential information disclosed by a party to the other party hereunder or as a result of this Agreement, including the terms and conditions
set forth herein, will be kept in the strictest confidence and will not, without the prior written consent of the disclosing party, be used by the receiving party or be disclosed to, or discussed with, any third party whatsoever. The above
undertaking of confidentiality will not apply to information which: (i) is in the public domain at the time of disclosure; or (ii) subsequently becomes part of the public domain, except by breach by the receiving party of its obligations,
or (iii) is received from a third party who is not under an obligation of confidentiality to the disclosing party. VBL may disclose, on a confidential basis, the terms of this Agreement to its Board of Directors, shareholders, potential
investors, acquirers or licensees in the process of due diligence reviews of its contracted obligations, assets and undertakings. 

  

	 	7.8	THM hereby declares that Sheba’s management reached an understanding with the management of Tel Aviv University (“TAU”), that as between the Hospital and TAU, inventions of TAU professors who work
as medical doctors for Sheba such as Prof. Dror Charats, Prof. Shoenfeld and Prof. Gerge Jacob, shall belong to Sheba. 


  
 11 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 [Remainder of the Page was left intentionally blank] 

  
 12 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and each of the
undersigned hereby warrants and represents that it has been and is, on the date of this Agreement, duly authorized by all necessary and appropriate action to execute this Agreement. 

 

											
	Tel Hashomer - Medical Research,	 		 		 	Vascular Biogenics Ltd.
	Infrastructure and Services Ltd.	 		 		 	
						
	By:	 	 [Illegible]
	 		 		 	By:	 	 /s/ Dror Harats

					
	 /s/ Dror Harats

Prof. Dror Harats
	 		 		 		 	
					
	Approved and Acknowledged	 		 		 		 	
					
	 [Illegible]

The Government of Israel
 By the Ministry of Health
	 		 		 		 	


  
 13 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 Appendix A 

INVENTORS 
 1. Prof. Dror Harats

 2. Shoenfeld Yehuda 
 3. George Jacob 

4. Halperin Gideon – up to 2003 
 5. Bloom Nira 

6. Greenberger Shoshana 
 7. Tal Reshef 

8. Peled Michael 
  

	*	detailed list of inventions is provided under Appendix B. 


  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 Appendix B’ up to 3 Feb 2013 

 

																	
	 METHODS AND COMPOSITIONS FOR ENHANCING TARGETING OF VIRAL VECTORS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 ISOLATED POLYNUCLEOTIDES AND NUCLEIC ACID CONSTRUCTS FOR DIRECTING EXPRESSION OF A GENE-OF-INTEREST IN CELLS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry
Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	
									
	 52423
	  	PCT	  	19-Oct-2010	  		  	12/10/2011	  		  	3182.041PC01	  	Pending	  	

  

																	
	 TREATMENT WITH VB-201
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry
Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50378
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000012
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083469
	 	3182.018PC05	  	Expired	  	YACOV Niva; BREITBART
 Eyal; MENDEL Itzhak; FEIGE

Erez; COHEN Yael



  
  

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 PAF-LIKE HOMOLOGS AND USES THEREOF
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44504
	  	PCT	  	16-Oct-2007
 60/960,846
	  		  	05-Oct-2008
 IL2008/001315
	  	Publ. Date: 23-Apr-2009

Publ. #: WO2009/050692
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48215
	  	Israel
 NP
	  	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 205144
	  		 	3182.019IL01	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48216
	  	USA
 NP
	  	16-Oct-2007
 60/960,846
	  	15-Apr-2010	  	05-Oct-2008
 12/738,097
	  		 	3182.0190001	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak
	 48217
	  	Europe
 NP
	  	16-Oct-2007
 60/960,846
	  	14-May-2010	  	05-Oct-2008
 08808113.8
	  		 	3182.019EP01	  	Aban	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak

  

																	
	 IMPROVED SYNTHESIS OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	


  
 3 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 28367
	  	PCT	  	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 IL2005/000735
	  	Publ. Date: 19-Jan-2006

Publ. #: WO2006/006161
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33799
	  	Israel
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005	  	1-Mar-2012
 180628
	 	3182.020IL00	  	GRANTED	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50430
	  	Israel
 DIV
	  	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211795
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50431
	  	Israel
 DIV
	  	09-Jul-2004
 60/586,219
	  	17-Mar-2011	  	10-Jul-2005
 211796
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793
	  	Europe
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 05758938.4
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793 Div
	  	Europe
 Div
	  	09-Jul-2004
 60/586,219
	  	Oct 2012	  	10-Jul-2005	  		 	3182.020EP10	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33793 Div
	  	Europe
 Div
	  	09-Jul-2004
 60/586,219
	  	Oct 2012	  	10-Jul-2005
 12179533.0
	  		 	3182.020EP20	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 39643
	  	Hong Kong
 NP
	  	09-Jul-2004
 60/586,219
	  	31-May-2007	  	10-Jul-2005
 07105789.7
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33795
	  	Canada
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2,573,396
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti


  
 4 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 33796
	  	Japan
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2007-519983
	  	24-Jun-2011
 4,767,948
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48896
	  	Japan
 DIV
	  	09-Jul-2004
 60/586,219
	  	21-May-2010	  	10-Jul-2005
 2010-116964
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33797
	  	Republic of Korea
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 2007-7003288
	  	9-Nov-2012
 10-1201935
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33798
	  	China
 NP
	  	09-Jul-2004
 60/586,219
	  	28-Feb-2007	  	10-Jul-2005
 200580029218.9
	  	3-Aug-2011
 200580029218.9
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48018
	  	China
 DIV
	  	09-Jul-2004
 60/586,219
	  	11-Feb-2010	  	10-Jul-2005
 201010128184.1
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 33801
	  	Russian Federation
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 2007105097
	  	20-Sep-2010
 2399626
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33802
	  	Mexico
 NP
	  	09-Jul-2004
 60/586,219
	  	08-Jan-2007	  	10-Jul-2005
 MX/a/2007/000361
	  	17-Mar-2011
 284830
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33803
	  	Australia
 DIV
	  	09-Jul-2004
 60/586,219
	  	09-Jan-2007	  	10-Jul-2005
 2007200090
	  	2007200090
 5 Jan 2012
	  	3182.020AU00	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 50536
	  	Mexico
 DIV
	  	09-Jul-2004
 60/586,219
	  	14-Jan-2011	  	10-Jul-2005
 MX/a/2011/000630
	  	3 Sep 2012
 303011
	  		  	Granetd	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti


  
 5 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 33804
	  	New Zealand
 NP
	  	09-Jul-2004
 60/586,219
	  	09-Feb-2007	  	10-Jul-2005
 553147
	  	06-Nov-2010
 553147
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48999
	  	New Zealand
 DIV
	  	09-Jul-2004
 60/586,219
	  	29-Jun-2010	  	10-Jul-2005
 586503
	  	10 Oct 2011
 586503
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 33805
	  	South Africa
 NP
	  	09-Jul-2004
 60/586,219
	  		  	10-Jul-2005
 2007/01178
	  	25-Sep-2008
 2007/01178
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti

  

																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 02/23345
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	01-May-2002
 10/135,447
	  	27-Jun-2006
 7,067,649
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 28786
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	29-Oct-2004	  	01-May-2002
 10/975,619
	  	25-Aug-2009
 7,579,327
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 45023
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	03-Jun-2009	  	01-May-2002
 12/457,200
	  		  		  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 50926
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	27-Apr-2011	  	01-May-2002
 13/094,900
	  		  		  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 53777
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	24-April
2012	  	01-May-2002
 13/454,171
	  		  	3182.0350004	  	Pending	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira


  
 6 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 25974
	  	PCT	  	01-May-2002
 10/135,447
	  		  	30-Apr-2003
 IL03/00347
	  	Publ. Date: 13-Nov-2003
 Publ. #:
WO03/093409
	 		  	Expired	  	HARATS
Dror
	 28650
	  	Singapore
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 200406381-4
	  	30-May-2008
 107841 [WO 03/093409]
	 		  	Granted	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 28655
	  	South Africa
 NP
	  	01-May-2002
 10/135,447
	  	05-Nov-2004	  	30-Apr-2003
 2004/8989
	  	26-Jul-2006
 2004/8989
	 		  	Granted	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 28646
	  	Japan
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 2004-501545
	  		 		  	Abandoned	  	HARATS
Dror
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 28651
	  	Canada
 NP
	  	01-May-2002
 10/135,447
	  	01-Nov-2004	  	30-Apr-2003
 2,483,996
	  		 		  	Abandoned	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 28652
	  	Mexico
 NP
	  	01-May-2002
 10/135,447
	  	28-Oct-2004	  	30-Apr-2003
 PA/a/2004/010711
	  		 		  	Abandoned	  	HARATS
Dror;
BREITBART
Eyal;
BLOOM
Nira
	 [* * *]
	  		  		  		  		  		 		  		  	


  
 7 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 COMBINED TREATMENT UTILIZING VB-201 

 

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50379
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000010
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083467
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	US
NP	  	05-Jan-2010
 61/292,226
	  	5-July 2012	  	05-Jan-2011
 13/520,713
	  		 	3182.0160005	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	EP
NP	  	05-Jan-2010
 61/292,226
	  	1-Aug 2012	  		  		 	3182.016EP05	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael
		  	JP
NP	  	05-Jan-2010
 61/292,226
	  	4-July 2012	  		  		 	3182.016JP05	  	Pending	  	YACOV Niva; BREITBART
Eyal; COHEN Yael

  

																	
	 POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH
ISCHEMIA
  

	 Our
Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 41795
	  	PCT	  	31-Jul-2006
 60/834,157
	  		  	31-Jul-2007
 IL2007/000959
	  	Publ. Date: 07-Feb-2008

Publ. #: WO/2008/015675
	 		  	Expired	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 45501
	  	China
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Mar-2009	  	31-Jul-2007
 200780035863.0
	  	8-Aug 2012
 ZL20078003 5863.0
	 	3182.040CN01	  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat


  
 8 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 54283
	  	China
 Div
	  	31-Jul-2006
 60/834,157
	  	26-June-2012	  	31-Jul-2007
 201210210646.3
	  		  	3182.040CN11	  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45495
	  	USA
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 12/309,856
	  		  		  	Abandoned	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 51521
	  	USA
 DIV
	  	31-Jul-2006
 60/834,157
	  	20-Jun-2011	  	31-Jul-2007
 13/163,776
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45496
	  	Israel
 NP
	  	31-Jul-2006
 60/834,157
	  	29-Jan-2009	  	31-Jul-2007
 196792
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 45499
	  	Australia
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 2007280017
	  	26-July 2012
 2007280017
	  	3182.040AU01	  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 54370
	  	Australia
 Div
	  	31-Jul-2006
 60/834,157
	  	12-July 2012	  	31-Jul-2007
 2012204128
	  		  	3182.040AU11	  	Pending	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat
	 45500
	  	Japan
 NP
	  	31-Jul-2006
 60/834,157
	  	02-Feb-2009	  	31-Jul-2007
 2009-522416
	  		  		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45502
	  	Republic of Korea
 NP
	  	31-Jul-2006
 60/834,157
	  	27-Feb-2009	  	31-Jul-2007
 2009-7004288
	  		  		  	Abandoned	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat


  
 9 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 45503
	  	Mexico
 NP
	  	31-Jul-2006
 60/834,157
	  	29-Jan-2009	  	31-Jul-2007
 MX/a/2009/001157
	  		 		  	Pending	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45504
	  	New Zealand
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Jan-2009	  	31-Jul-2007
 574410
	  	9 July 2012
 574410
	 	3182.040NZ01	  	Granted	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45505
	  	South Africa
 NP
	  	31-Jul-2006
 60/834,157
	  	26-Jan-2009	  	31-Jul-2007
 2009/00581
	  	31-Mar-2010
 2009/00581
	 		  	Granted	  	TAL Reshef; BREITBART
Eyal; BANGIO Livnat
	 45506
	  	Singapore
 NP
	  	31-Jul-2006
 60/834,157
	  	30-Jan-2009	  	31-Jul-2007
 200900642-0
	  	30-Jun-2011
 149616[WO2008/015675]
	 		  	Granted	  	TAL Reshef; BREITBART Eyal;
BANGIO Livnat

  

																	
	 TREATMENT WITH VB-201
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50377
	  	PCT	  	05-Jan-2010
 61/292,226
	  		  	05-Jan-2011
 IL2011/000008
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083465
	 		  	Expired	  	YACOV Niva; BREITBART
Eyal; MENDEL Itzhak; SHER
Naamit; COHEN Yael
		  	US NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		 	3182.0170005	  	Pending	  	
		  	AU NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		 	3182.017AU05	  	Pending	  	


  
 10 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	CANADA
NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017CA05	  	Pending	  	
		  	China
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017CN05	  	Pending	  	
		  	HK
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017HK05	  	Pending	  	
		  	EP NP	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017EP05	  	Pending	  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	Japan
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017JP05	  	Pending	  	
		  	South Korea
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017KR05	  	Pending	  	
		  	MX
 NP
	  	05-Jan-2010
 61/292,226
	  	June 2012	  	05-Jan-2011	  		  	3182.017MX05	  	Pending	  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	


  
 11 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 ANTI-ANGIOGENIC ADENOVIRUS VECTOR SUITABLE FOR CLINICAL APPLICATIONS AND METHODS FOR PRODUCTION THEREOF

  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS OF PRODUCING ADENOVIRUS VECTORS AND VIRAL
PREPARATIONS GENERATED THEREBY
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 49684
	  	PCT	  	12-Jan-2010
 61/294,158
	  		  	12-Jan-2011
 IB2011/050137
	  	Publ. Date: 21-Jul-2011

Publ. #: WO2011/086509
	 		  	Expired	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
		  	US NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.0330001	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
		  	EP NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.033EP01	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
	 [* * *]
	  		  		  		  		  		 		  		  	
		  	JP NP	  	12-Jan-2010
 61/294,158
	  	June 2012	  	12-Jan-2011	  		 	3182.033JP01	  	Pending	  	BREITBART
Eyal;
BANGIO
Livnat;
SHER
Naamit
	 [* * *]
	  		  		  		  		  		 		  		  	


  
 12 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 IMMUNOMODULATION (IMMUNIZATION AND TOLERANCE) OF APO-E DEFICIENT MICE WITH 1 HEXADECINYL 2-5’ OXOPENTYL
PHOSPHATIDYCHLOLINE (2-5 ALLE-ALDEHYDE LECITIN ETHER) SUPPRESSES EARLY ATHEROGENESIS 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED
OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/22753
	  	PCT	  	24-Nov-2000
 60/252,574
	  		  	22-Nov-2001
 IL01/01080
	  	Publ. Date: 30-May-2002
 Publ. #:
WO02/41827
	 		  	Expired	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26035
	  	Europe
 NP
	  	22-Nov-2000
 60/252,574
	  	15-May-2003	  	22-Nov-2001
 01997274.4
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 52529
	  	EP Div	  	22-Nov-2000
 60/252,574
	  	17-Nov 2011	  	22-Nov-2001
 11189562.9
	  		 	3182.021EP11	  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 27265
	  	Hong Kong
 NP
	  	24-Nov-2000
 60/252,574
	  	12-Dec-2003	  	22-Nov-2001
 03109096.1
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26036
	  	Israel
 NP
	  	22-Nov-2000
 60/252,574
	  	20-May-2003	  	22-Nov-2001
 156015
	  	10-May-2008
 156015
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 32434
	  	Israel
 DIV
	  	24-Nov-2000
 60/252,574
	  	20-Jul-2006	  	22-Nov-2001
 176976
	  	1-Dec 2012
 176976
	 	3182.021IL11	  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26037
	  	India
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 796/CHENP/2003
	  	19-Sep-2008
 223638
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon


  
 13 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 26039
	  	Canada
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 2,429,817
	  		  	3182.021CA01	  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26040
	  	Australia
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002218461
	  	21-Dec-2006
 2002218461
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26041
	  	Japan
 NP
	  	22-Nov-2000
 60/252,574
	  	23-May-2003	  	22-Nov-2001
 2002-544008
	  	01-Aug-2008
 4,162,486
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 44299
	  	Japan
 DIV
	  	24-Nov-2000
 60/252,574
	  	10-Jun-2008	  	22-Nov-2001
 2008-151301
	  	25 May 2012
 5001906
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26042
	  	China
 NP
	  	22-Nov-2000
 60/252,574
	  	22-Jul-2003	  	22-Nov-2001
 01822215.3
	  	06-Jan-2010
 ZL01822215.3
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26043
	  	Republic of Korea
 NP
	  	22-Nov-2000
 60/252,574
	  	24-May-2003	  	22-Nov-2001
 2003-7006991
	  	17-Oct-2008
 865142
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 26044
	  	Mexico
 NP
	  	22-Nov-2000
 60/252,574
	  	22-May-2003	  	22-Nov-2001
 PA/a/2003/004517
	  	02-Sep-2009
 269738
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon
	 46494
	  	Mexico
 DIV
	  	24-Nov-2000
 60/252,574
	  	12-Jun-2009	  	22-Nov-2001
 MX/a/2009/006365
	  	2 December 2011
 293020
	  	3182.021MX11	  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN Gideon


  
 14 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 36194
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	30-Apr-2007
 11/790,992
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 43177
	  	PCT	  	30-Apr-2007
 11/790,992
	  		  	27-Apr-2008
 IL2008/000543
	  	Publ. Date: 06-Nov-2008

Publ. #: WO2008/132729
	 		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART
Eyal; BANGIO Livnat;
PELED Michael
	 47030
	  	Europe
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 08738245.3
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 48882
	  	Hong Kong
 NP
	  	30-Apr-2007
 11/790,992
	  	11-Jun-2010	  	27-Apr-2008
 10105838.3
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47031
	  	Japan
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Oct-2009	  	27-Apr-2008
 2010-505002
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47032
	  	Canada
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Oct-2009	  	27-Apr-2008
 2,685,394
	  		 		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47033
	  	China
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Dec-2009	  	27-Apr-2008
 200880022935.2
	  		 	3182.039CN01	  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael


  
 15 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 47034
	  	Australia
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 2008243817
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47035
	  	Republic of Korea
 NP
	  	30-Apr-2007
 11/790,992
	  	18-Nov-2009	  	27-Apr-2008
 2009-7024041
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 [* * *]
	  		  		  		  		  		  		  		  	
	 47037
	  	Israel
 NP
	  	30-Apr-2007
 11/790,992
	  	26-Oct-2009	  	27-Apr-2008
 201760
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47038
	  	Mexico
 NP
	  	30-Apr-2007
 11/790,992
	  	29-Oct-2009	  	27-Apr-2008
 MX/a/2009/011750
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47039
	  	New Zealand
 NP
	  	30-Apr-2007
 11/790,992
	  	27-Nov-2009	  	27-Apr-2008
 581511
	  	5 June 2012
 581511
	  	3182.039NZ01	  	Granetd	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47040
	  	South Africa
 NP
	  	30-Apr-2007
 11/790,992
	  	25-Nov-2009	  	27-Apr-2008
 2009/08331
	  	29-Dec-2010
 2009/08331
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael
	 47041
	  	Singapore
 NP
	  	30-Apr-2007
 11/790,992
	  	30-Oct-2009	  	27-Apr-2008
 200907209-1
	  	15 May 2012
 156740
	  	3182.039SG01	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal;
BANGIO Livnat; PELED
Michael


  
 16 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 THE EFFECT OF MUCOSAL TOLERANCE WITH LIPID IPOPROTEIN AND PROTEIN ANTIGENS ON ATHEROSCLEROSIS IN LDL-RECEPTOR
DEFICIENT MICE 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	  
 METHODS EMPLOYING AND COMPOSITIONS CONTAINING PLAQUE
ASSOCIATED MOLECULES FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/23033
	  	PCT	  	04-Jan-2001
 60/259,512
	  		  	03-Jan-2002
 IL02/00005
	  	Publ. Date: 11-Jul-2002
 Publ. #:
WO02/053092
	 		  	Expired	  	HARATS Dror; GEORGE
Jacob
	 26046
	  	Israel
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 156770
	  		 		  	Allowed	  	HARATS Dror; GEORGE
Jacob
	 26047
	  	India
 NP
	  	04-Jan-2001
 60/259,512
	  	04-Jul-2003	  	03-Jan-2002
 1044/CHENP/2003
	  	19-Sep-2008
 223640
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26048
	  	USA
 NP
	  	04-Jan-2001
 60/259,512
	  	02-Jul-2003	  	03-Jan-2002
 10/451,370
	  	09-Oct-2007
 7,279,459
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26050
	  	Australia
 NP
	  	04-Jan-2001
 60/259,512
	  	11-Jul-2003	  	03-Jan-2002
 2002225301
	  	03-Mar-2006
 2002225301
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26051
	  	Japan
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 2002-554043
	  	26-Sep-2008
 4,191,997
	 		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26052
	  	China
 NP
	  	04-Jan-2001
 60/259,512
	  	04-Sep-2003	  	03-Jan-2002
 02805950.6
	  		 		  	Pending	  	HARATS Dror; GEORGE
Jacob


  
 17 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 26054
	  	Mexico
 NP
	  	04-Jan-2001
 60/259,512
	  	01-Jun-2003	  	03-Jan-2002
 PA/a/2003/006043
	  	17-Mar-2009
 265173
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob
	 26045
	  	Europe
 NP
	  	04-Jan-2001
 60/259,512
	  	18-Jul-2003	  	03-Jan-2002
 02715682.7
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 27463
	  	Hong Kong
 NP
	  	04-Jan-2001
 60/259,512
	  	28-Jan-2004	  	03-Jan-2002
 04100565.1
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 26049
	  	Canada
 NP
	  	04-Jan-2001
 60/259,512
	  	03-Jul-2003	  	03-Jan-2002
 2,433,781
	  		  		  	Abandoned	  	HARATS Dror; GEORGE
Jacob
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 FORMULATIONS AND DOSAGE FORMS OF CI-201 AND RELATED COMPOUNDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	PCT	  	Sept. 1, 2011
 61/529,989
	  		  	Aug. 31, 2012
 PCT/US2012/053533
	  		  	3182.013PC01	  	Pending	  	SHER Naamit; YOUNG Victor
M.; McNAUGHTON Alyn;
WILDING Ian; BAKHSHAEE
Massoud


  
 18 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	 	  	Status	  	Inventor
	 31577
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	23-Feb-2006
 11/359,513
	  	18 October 2011
 8,039,261
	 	3182.0380000	  	Granted	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael
	 37180
	  	PCT	  	23-Feb-2006
 11/359,513
	  		  	22-Feb-2007
 IL2007/000242
	  	Publ. Date: 30-Aug-2007

Publ. #: WO2007/096882
	 		  	Expired	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44720
	  	USA
 NP
	  	17-Nov-2000
 60/248,582
	  	20-Aug-2008	  	22-Feb-2007
 12/224,178
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
BANGIO Livnat; PELED Michael
	 44708
	  	Europe
 NP
	  	23-Feb-2006
 11/359,513
	  	28-Aug-2008	  	22-Feb-2007
 07713267.8
	  		 		  	Pending	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44709
	  	Israel
 NP
	  	23-Feb-2006
 11/359,513
	  	19-Aug-2008	  	22-Feb-2007
 193554
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		 		  		  	
	 44711
	  	Canada
 NP
	  	23-Feb-2006
 11/359,513
	  	20-Aug-2008	  	22-Feb-2007
 2,638,829
	  		 		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat


  
 19 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 44712
	  	Australia
 NP
	  	23-Feb-2006
 11/359,513
	  	23-Sep-2008	  	22-Feb-2007
 2007219088
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44713
	  	Japan
 NP
	  	23-Feb-2006
 11/359,513
	  	25-Aug-2008	  	22-Feb-2007
 2008-555946
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44714
	  	China
 NP
	  	23-Feb-2006
 11/359,513
	  	21-Oct-2008	  	22-Feb-2007
 200780014285.2
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44715
	  	Republic of Korea
 NP
	  	23-Feb-2006
 11/359,513
	  	22-Sep-2008	  	22-Feb-2007
 2008-7023144
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 44716
	  	Mexico
 NP
	  	23-Feb-2006
 11/359,513
	  	22-Aug-2008	  	22-Feb-2007
 MX/a/2008/010859
	  		  		  	Abandoned	  	HARATS Dror; GREENBERGER
Shoshana; BREITBART Eyal;
PELED Michael; BANGIO Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 33794
	  	USA CIP	  	09-Jul-2004
 60/586,219
	  		  	09-Jan-2007
 11/650,973
	  	05-Oct-2010
 7,807,847
	  	3182.0200001	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 49396
	  	USA DIV	  	09-Jul-2004
 60/586,219
	  	24-Aug-2010	  	09-Jan-2007
 12/861,921
	  	28-Feb 2012
 8,124,800
	  	3182.0200002	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti


  
 20 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 52800
	  	USA DIV	  	09-Jul-2004
 60/586,219
	  	May 24, 2012	  	January 26, 2012
 13/358,573
	  		  	3182.0200003	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI
		  	USA CIP	  	09-Jul-2004
 60/586,219
	  		  	Nov. 9, 2012
 13/672,811
	  		  	3182.0200004	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI
		  	US CON	  	09-Jul-2004
 60/586,219
	  		  	Dec. 10, 2012
 13/709,198
	  		  	3182.0200005	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI

  

																	
	 IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 43029
	  	PCT	  	09-Jan-2007
 11/650,973
	  		  	02-Jan-2008
 IL2008/000013
	  	Publ. Date: 17-Jul-2008
 Publ. #: WO2008/084472
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46756
	  	South Africa
 NP
	  	09-Jan-2007
 11/650,973
	  		  	02-Jan-2008
 2009/05601
	  	26-May-2010
 2009/05601
	 		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46755
	  	New Zealand
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 578947
	  	4-Dec 2011
 578947
	 	3182.020NZ01	  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 51026
	  	New Zealand
 DIV
	  	09-Jan-2007
 11/650,973
	  	15-Jun-2011	  	02-Jan-2008
 593529
	  		 	3182.020NZ11	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		 		  		  	


  
 21 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 46754
	  	Australia
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 2008204238
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46753
	  	Mexico
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 MX/a/2009/007422
	  	9-Jan 2012
 294470
	  		  	Granted	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 [* * *]
	  		  		  		  		  		  		  		  	
	 46751
	  	Israel
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 199792
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46750
	  	China
 NP
	  	09-Jan-2007
 11/650,973
	  	31-Aug-2009	  	02-Jan-2008
 200880006707.6
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46749
	  	Republic of Korea
 NP
	  	09-Jan-2007
 11/650,973
	  	27-Jul-2009	  	02-Jan-2008
 2009-7015780
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46748
	  	Japan
 NP
	  	09-Jan-2007
 11/650,973
	  	09-Jul-2009	  	02-Jan-2008
 2009-545295
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46747
	  	Canada
 NP
	  	09-Jan-2007
 11/650,973
	  	06-Jul-2009	  	02-Jan-2008
 2,674,902
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 46746
	  	Europe
 NP
	  	09-Jan-2007
 11/650,973
	  	07-Aug-2009	  	02-Jan-2008
 08700247.3
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
		  	Europe
 Div
	  	09-Jan-2007
 11/650,973
	  	July 27, 2012	  	02-Jan-2008
 EP 12178298.1
	  		  	3182.020EP11	  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti
	 48328
	  	Hong Kong
 NP
	  		  	16-Mar-2010	  	02-Jan-2008
 10102729.2
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti


  
 22 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	
	  
 METHODS FOR USE OF A SPECIFIC ANTI-ANGIOGENIC
ADENOVIRAL AGENT
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50375
	  	PCT	  	05-Jan-2010
 61/282,228
	  		  	05-Jan-2011
 IL2011/000007
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083464
	 		  	Expired	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	US NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.0310002	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	EP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031EP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	IL	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031IL02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
	 [* * *]
	  		  		  		  		  		 		  		  	
		  	JP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		 	3182.031JP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael


  
 23 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	MX	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031MX02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	Canada	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031CA02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael
		  	Au	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.031AU02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; SHER Naamit; FEIGE
Erez; COHEN Yael

  

																	
	 COMPOSITIONS AND METHODS FOR TREATING GLIOBLASTOMA GBM

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50376
	  	PCT	  	05-Jan-2010
 61/282,228
	  		  	05-Jan-2011
 IL2011/000009
	  	Publ. Date: 14-Jul-2011

Publ. #: WO2011/083466
	 	3182.032PC02	  	Expired	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.


  
 24 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
		  	US NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.0320002	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	EU NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032EP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	IL NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032IL02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	JP NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032JP02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	KR NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032KR02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	MX NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032MX02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
		  	CA NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032CA02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.
		  	AU NP	  	05-Jan-2010
 61/282,228
	  	June 2012	  	05-Jan-2011	  		  	3182.032AU02	  	Pending	  	BREITBART Eyal; BANGIO
Livnat; COHEN Yael;
BRENNER Andrew J.


  
 25 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	 	  	Status	  	Inventor
	 32516
	  	USA
 CIP
	  	27-May-2003
 10/445,347
	  		  	28-Sep-2006
 11/528,657
	  	01-Dec-2009
 7,625,882
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak
	 46643
	  	USA
 DIV
	  	27-May-2003
 10/445,347
	  	14-Oct-2009	  	28-Sep-2006
 12/588,371
	  	05-Jul-2011
 7,973,023
	  		  	Granted	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak
	 50968
	  	USA
 CON
	  	27-May-2003
 10/445,347
	  	13-Apr-2011	  	28-Sep-2006
 13/085,542
	  		  		  	Pending	  	HARATS Dror; GEORGE
Jacob; HALPERIN
Gideon; KOVALEVSKI-
ISHAI Eti; YACOV Niva;
MENDEL Itzhak

  

																	
	 AN IMMUNOLOGICAL AND ORAL TOLERANCE-INDUCING COMPOSITION AND USE THEREOF FOR THE PREVENTION AND/OR FOR THE TREATMENT OF
ATHEROSCLEROSIS
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 00/21414
	  	Israel
 Basic
	  		  		  	04-Oct-1998
 126447
	  	30-Dec-2004
 126447
	  		  	Granted	  	HARATS Dror; SHOENFELD
Yehuda; GEORGE Jacob


  
 26 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 A COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS 

 

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 01/21558
	  	PCT	  	04-Oct-1998
 126447
	  	01-Apr-2001	  	30-Sep-1999
 IL99/00519
	  	Publ. Date: 13-Apr-2000
 Publ. #:
WO00/20019
	 		  	Expired	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21884
	  	Europe
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 99970026.3
	  	14-May-2003
 1126867
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21886
	  	Canada
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2,345,445
	  	24-Aug-2010
 2,345,445
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21887
	  	Australia
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 59966/99
	  	28-Aug-2003
 760582
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21888
	  	China
 NP
	  	04-Oct-1998
 126447
	  	04-Apr-2001	  	30-Sep-1999
 99814030.9
	  	24-Nov-2004
 ZL99814030.9
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 02/23904
	  	Hong Kong
 NP
	  	04-Oct-1998
 126447
	  	19-Jul-2002	  	30-Sep-1999
 02105365.4
	  	18-Nov-2005
 HK1043743
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 28590
	  	China
 DIV
	  	04-Oct-1998
 126447
	  	23-Sep-2004	  	30-Sep-1999
 200410011940.7
	  	05-Nov-2008
 ZL200410011940.7
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 30562
	  	Hong Kong
 DIV
	  	04-Oct-1998
 126447
	  	28-Sep-2005	  	30-Sep-1999
 05108561.7
	  	21-Aug-2009
 HK1076600
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21889
	  	Singapore
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 200101998-3
	  	30-Apr-2003
 80182
	 		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob



  
 27 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 01/21890
	  	Japan
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2000-573378
	  		  		  	Pending	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21891
	  	Hungary
 NP
	  	04-Oct-1998
 126447
	  	30-Sep-1999	  	30-Sep-1999
 P0104410
	  		  		  	Pending	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 [* * *]
	  		  		  		  		  		  		  		  	
	 01/21893
	  	Republic of Korea
 NP
	  	04-Oct-1998
 126447
	  		  	30-Sep-1999
 2001-7004285
	  	02-Feb-2007
 680707
	  		  	Granted	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/21885
	  	USA
 NP
	  	04-Oct-1998
 126447
	  	30-Mar-2001	  	30-Sep-1999
 09/806,400
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	 01/22498
	  	USA
 CON
	  	04-Oct-1998
 126447
	  	04-Sep-2001	  	30-Sep-1999
 09/944,592
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE
Jacob

	  
 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE
PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 28919
	  	USA
 CIP
	  	04-Oct-1998
 126447
	  		  	15-Apr-2005
 11/106,665
	  		  		  	Abandoned	  	 HARATS Dror; SHOENFELD
 Yehuda; GEORGE Jacob;

YACOV Niva



  
 28 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF
ATHEROSCLEROSIS 
  

																	
	 Our Ref
	  	Country	  	Earliest
      Priority      	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	  	SKGF Ref	  	Status	  	 Inventor

	 26038
	  	USA
 CIP
	  	22-Nov-2000
 60/252,574
	  		  	27-May-2003
 10/445,347
	  	04-Jan-2005
 6,838,452
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti; YACOV Niva

	 27041
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	24-Nov-2003	  	27-May-2003
 10/718,596
	  	06-Mar-2007
 7,186,704
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 29890
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	19-Jul-2005	  	27-May-2003
 11/183,884
	  	17-Mar-2009
 7,504,388
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 45347
	  	USA
 DIV
	  	24-Nov-2000
 60/252,574
	  	17-Feb-2009	  	27-May-2003
 12/371,930
	  	22-Feb-2011
 7,893,291
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 50439
	  	USA
 CON
	  	24-Nov-2000
 60/252,574
	  	06-Jan-2011	  	27-May-2003
 12/985,365
	  	17 April
 20128,158,611
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 53355
	  	USA
 CON
	  	24-Nov-2000
 60/252,574
	  	March 27, 2012	  	27-May-2003
 13/431,262
	  		  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV
Niva



  
 29 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	  
 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF
INFLAMMATORY DISEASES AND DISORDERS
  

	 Our Ref
	 	Country	  	    Earliest Priority    	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	 	SKGF Ref	  	Status	  	 Inventor

	 27909
	 	PCT	  	27-May-2003
 10/445,347
	  		  	27-May-2004
 IL2004/000453
	  	Publ. Date: 09-Dec-2004

Publ. #: WO2004/106486
	 		  	Expired	  	 HARATS Dror; GEORGE
 Jacob;
HALPERIN Gideon

	 31532
	 	USA
 NP
	  	27-May-2003
 10/445,347
	  	25-Apr-2008	  	27-May-2004
 10/567,543
	  	08-Mar-2011
 7,902,176
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon;
 KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30958
	 	Mexico
 NP
	  	27-May-2003
 10/445,347
	  	25-Nov-2005	  	27-May-2004
 pa/A/2005/012784
	  	14-Oct-2008
 261341
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon

	 [* * *]
	 		  		  		  		  		 		  		  	
	 30947
	 	Europe
 NP
	  	27-May-2003
 10/445,347
	  	07-Dec-2005	  	27-May-2004
 04735088.9
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 32340
	 	Hong Kong
 NP
	  	27-May-2003
 10/445,347
	  	03-Aug-2006	  	27-May-2004
 06108608.1
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30948
	 	Japan
 NP
	  	27-May-2003
 10/445,347
	  	30-Nov-2005	  	27-May-2004
 2006-531006
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 [* * *]
	 		  		  		  		  		 		  		  	
	 30949
	 	Canada
 NP
	  	27-May-2003
 10/445,347
	  	28-Nov-2005	  	27-May-2004
 2,527,483
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30950
	 	China
 NP
	  	27-May-2003
 10/445,347
	  	01-Nov-2005	  	27-May-2004
 200480021217.5
	  	22-Dec-2010
 ZL200480021217.5
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV
Niva



  
 30 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 49865
	 	China
 DIV
	  	27-May-2003
 10/445,347
	  	25-Oct-2010	  	27-May-2004
 201010537971.1
	  		  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN
Gideon;
 KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30951
	 	Australia
 NP
	  	27-May-2003
 10/445,347
	  	13-Dec-2005	  	27-May-2004
 2004243695
	  	17-Mar-2011
 2004243695
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30952
	 	Republic of Korea
 NP
	  	27-May-2003
 10/445,347
	  	28-Nov-2005	  	27-May-2004
 2005-7022741
	  	3-Nov 2011
 1081977
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 50809
	 	Republic of Korea
 DIV
	  	27-May-2003
 10/445,347
	  	18-Feb-2011	  	27-May-2004
 2011-7003840
	  	23 Feb 2012
 10-1122160
	  		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30953
	 	New Zealand
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 544285
	  	12-Mar-2009
 544285
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30954
	 	South Africa
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 2005/09929
	  	27-Dec-2006
 2005/9929
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 30955
	 	India
 NP
	  	27-May-2003
 10/445,347
	  	27-Dec-2005	  	27-May-2004
 3555/CHENP/2005
	  	26-Mar-2009
 232654
	  		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 [* * *]
	 		  		  		  		  		  		  		  	


  
 31 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 [* * *]
	 		  		  		  		  		 		  		  	
	 30957
	 	Russian Federation
 NP
	  	27-May-2003
 10/445,347
	  	01-Dec-2005	  	27-May-2004
 2005140666
	  	27-Jul-2009
 2362567
	 		  	Granted	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	 46052
	 	Russian Federation
 DIV
	  	27-May-2003
 10/445,347
	  	06-Apr-2009	  	27-May-2004
 2009112686
	  		 		  	Pending	  	 HARATS Dror; GEORGE
 Jacob; HALPERIN Gideon;

KOVALEVSKI-ISHAI Eti;
 YACOV Niva

	  
 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES
THEREOF
  

	 Our Ref
	 	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	 Inventor

	 [* * *]
	 		  		  		  		  		 		  		  	
	 46530
	 	PCT	  	08-Oct-2008
 61/103,571
	  		  	01-Oct-2009
 IL2009/000949
	  	Publ. Date: 15-Apr-2010

Publ. #: WO2010/041242
	 		  	Expired	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50053
	 	USA
 NP
	  	08-Oct-2008
 61/103,571
	  	06-Apr-2011	  	01-Oct-2009
 13/122,766
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez

	 50054
	 	Europe
 NP
	  	08-Oct-2008
 61/103,571
	  	20-Apr-2011	  	01-Oct-2009
 09818874.1
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE
Erez



  
 32 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 50055
	 	Israel
 NP
	  	08-Oct-2008
 61/103,571
	  	05-Apr-2011	  	01-Oct-2009
 212153
	  		 		  	Pending	  	 HALPERIN Gideon;
 KOVALEVSKI-ISHAI Eti;

BREITBART Eyal; MENDEL
 Itzhak; ZINIUK Zeev; FEIGE

Erez

	  
 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I-DERIVED
PEPTIDES FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE
  

	 Our Ref
	 	Country	  	      Earliest Priority      	  	      Entry Date      	  	Filing Date
  Application No.  	  	Issue Date
    Patent No.    	 	SKGF Ref	  	Status	  	 Inventor

	 [* * *]
	 		  		  		  		  		 		  		  	
	 31865
	 	PCT	  	15-Apr-2005
 60/671,500
	  		  	11-Apr-2006
 IL2006/000467
	  	Publ. Date: 19-Oct-2006

Publ. #: WO2006/109312
	 		  	Expired	  	 YACOV Niva; BREITBART
 Eyal

	 41853
	 	Europe
 NP
	  	15-Apr-2005
 60/671,500
	  	24-Oct-2007	  	11-Apr-2006
 06728268.1
	  		 		  	Abandoned	  	 YACOV Niva; BREITBART
 Eyal

	 41854
	 	USA
 NP
	  	15-Apr-2005
 60/671,500
	  	10-Oct-2007	  	11-Apr-2006
 11/918,141
	  		 		  	Abandoned	  	 YACOV Niva; BREITBART
 Eyal

	 [* * *]
	 		  		  		  		  		 		  		  	
	 [* * *]
	 		  		  		  		  		 		  		  	

 NOVEL DERIVATIVES OF OXIDIZED PHOSPHOLIPIDS 

  
 33 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		 		  		  	
	
	OXIDIZED LIPID COMPOUNDS AND USES THEREOF
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 45018
	  	PCT	  	06-Nov-2008
 61/193,220
	  		  	05-Nov-2009
 IL2009/001049
	  	Publ. Date: 14-May-2010

Publ. #: WO2010/052718
	 		  	Expired	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50603
	  	USA
 NP
	  	06-Nov-2008
 61/193,220
	  	05-May-2011	  	05-Nov-2009
 13/127,717
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		 		  		  	
	 50605
	  	Europe
 NP
	  	06-Nov-2008
 61/193,220
	  	16-May-2011	  	05-Nov-2009
 09824498.1
	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 51983
	  	Hong Kong
 NP
	  		  		  	05-Nov-2009	  		 		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez


  
 34 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 50606
	  	Canada
 NP
	  	06-Nov-2008
 61/193,220
	  	13-Apr-2011	  	05-Nov-2009
 2,740,726
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		  		  		  	
	 50608
	  	Australia
 NP
	  	06-Nov-2008
 61/193,220
	  	15-Apr-2011	  	05-Nov-2009
 2009312355
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50609
	  	New Zealand
 NP
	  	06-Nov-2008
 61/193,220
	  	19-Apr-2011	  	05-Nov-2009
 592357
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 [* * *]
	  		  		  		  		  		  		  		  	
	 50611
	  	Japan
 NP
	  	06-Nov-2008
 61/193,220
	  	06-May-2011	  	05-Nov-2009	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50612
	  	Republic of Korea
 NP
	  	06-Nov-2008
 61/193,220
	  	02-Jun-2011	  	05-Nov-2009
 2011-7012700
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez


  
 35 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 50613
	  	Mexico
 NP
	  	06-Nov-2008
 61/193,220
	  	04-May-2011	  	05-Nov-2009
 MX/a/2011/004773
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50614
	  	Russian Federation
 NP
	  	06-Nov-2008
 61/193,220
	  	06-Jun-2011	  	05-Nov-2009
 2011122729
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez
	 50615
	  	China
 NP
	  	06-Nov-2008
 61/193,220
	  	30-Jun-2011	  	05-Nov-2009
 200980153378.2
	  		  		  	Pending	  	HALPERIN Gideon;
KOVALEVSKI-ISHAI Eti;
YACOV Niva;
BREITBART Eyal;
MENDEL Itzhak; ZINIUK
Zeev; FEIGE Erez

 ENDOTHELIAL-SPECIFIC APOPTOSIS INDUCED BY AN ADENOVIRAL VECTOR CONTAINING A CHIMERIC RECEPTOR DRIVEN BY A TISSUE SPECIFIC
PROMOTER 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	 Issue Date

Patent No.
	  	SKGF Ref	  	Status	  	Inventor
									
	 [* * *]
	  		  		  		  		  		  		  		  	
	
	POLYNUCLEOTIDE CONSTRUCTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TARGETED DOWNREGULATION OF ANGIOGENESIS AND ANTICANCER THERAPY
									
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	 Issue Date

Patent No.
	  	SKGF Ref	  	Status	  	Inventor
	 02/23346
	  	PCT	  	19-Oct-2001
 60/330,118
	  		  	01-May-2002
 IL02/00339
	  	 Publ. Date: 24-Apr-2003

Publ. #: WO03/033514
	  		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana
	 27526
	  	USA
 NP
	  	19-Oct-2001
 60/330,118
	  	12-Apr-2004	  	01-May-2002
 10/490,746
	  	 08-Sep-2009
 7,585,666
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal


  
 36 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 44506
	  	USA
 DIV
	  	19-Oct-2001
 60/330,118
	  	08-Aug-2008	  	01-May-2002
 12/222,439
	  	 02-Aug-2011
 7,989,427
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 51506
	  	USA
 DIV
	  	19-Oct-2001
 60/330,118
	  	20-Jun-2011	  	01-May-2002
 13/163,767
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27527
	  	Europe
 NP
	  	19-Oct-2001
 60/330,118
	  	21-Apr-2004	  	01-May-2002
 02801473.6
	  	 22-Sep-2010
 1436313
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 29028
	  	Hong Kong
 NP
	  	19-Oct-2001
 60/330,118
	  	06-Jan-2005	  	01-May-2002
 05100081.5
	  	 01-Apr-2011
 HK1067641
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 49785
	  	Europe
 DIV
	  	19-Oct-2001
 60/330,118
	  	17-Sep-2010	  	01-May-2002
 EP10177257.2
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 47553
	  	Europe
 DIV
	  	19-Oct-2001
 60/330,118
	  	18-Nov-2009	  	01-May-2002
 09176343.3
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 49931
	  	Hong Kong
 DIV
	  	19-Oct-2001
 60/330,118
	  	10-Dec-2010	  	01-May-2002
 10111522.2
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 51004
	  	Hong Kong
 DIV
	  	19-Oct-2001
 60/330,118
	  	27-Apr-2011	  	01-May-2002
 11104228.3
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27528
	  	Japan
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 2003-536253
	  	 22-Aug-2008
 4,173,446
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal


  
 37 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 27529
	  	Republic of Korea
 NP
	  	19-Oct-2001
 60/330,118
	  	17-Apr-2004	  	01-May-2002
 2004-7005720
	  	 24-Oct-2008
 866117
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27530
	  	India
 NP
	  	19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	01-May-2002
 801/CHENP/2004
	  	 26-Dec-2008
 226357
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27531
	  	China
 NP
	  	19-Oct-2001
 60/330,118
	  	09-Jun-2004	  	01-May-2002
 02824547.4
	  	 01-Jul-2009
 ZL02824547.4
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 46077
	  	China
 DIV
	  	19-Oct-2001
 60/330,118
	  	27-Apr-2009	  	01-May-2002
 200910137707.6
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27532
	  	Singapore
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 200402237-2
	  	 31-May-2006
 103725
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27533
	  	Canada
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 2,463,816
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27534
	  	Mexico
 NP
	  	19-Oct-2001
 60/330,118
	  	19-Apr-2004	  	01-May-2002
 PA/a/2004/003514
	  	 12-Nov-2010
 280956
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 [* * *]
	  		  		  		  		  		  		  		  	
	 27535
	  	Australia
 NP
	  	19-Oct-2001
 60/330,118
	  	20-Apr-2004	  	01-May-2002
 2002307793
	  	 17-May-2007
 2002307793
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27536
	  	New Zealand
 NP
	  	19-Oct-2001
 60/330,118
	  	16-Apr-2004	  	01-May-2002
 532348
	  	 12-Oct-2006
 532348
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal
	 27537
	  	South Africa
 NP
	  	19-Oct-2001
 60/330,118
	  	08-Apr-2004	  	01-May-2002
 2004/2756
	  	 31-May-2006
 2004/02756
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal


  
 38 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 USING A MINI-GENE CONSTRUCT (3X-PPR-1) FOR ENDOTHELIAL CELLS SPECIFIC GENE THERAPY. IMPLICATIONS IN
CARDIOVASCULAR, CANCER AND WOUND HEALING 
  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		 		  		  	
		  		  		  		  		  		 		  		  	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	SKGF Ref	  	Status	  	Inventor
	 01/22752
	  	PCT	  	17-Nov-2000
 60/248,582
	  		  	15-Nov-2001
 IL01/01059
	  	Publ. Date: 23-May-2002
 Publ. #:
WO02/40629
	 		  	Expired	  	HARATS Dror
	 26025
	  	Europe
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 01996590.4
	  	20-Jan-2010
 1443970
	 		  	Granted	  	HARATS Dror; BLOOM Nira
	 29027
	  	Hong Kong
 NP
	  	17-Nov-2000
 60/248,582
	  	12-Jan-2005	  	15-Nov-2001
 05100240.3
	  	20-Aug-2010
 HK1068057
	 		  	Granted	  	HARATS Dror; BLOOM Nira
	 47088
	  	Europe
 DIV
	  	17-Nov-2000
 60/248,582
	  	04-Nov-2009	  	15-Nov-2001
 09174998.6
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira
	 49806
	  	Europe
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Oct-2010	  	15-Nov-2001
 EP10185193.9
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira
	 49498
	  	Hong Kong
 DIV
	  	17-Nov-2000
 60/248,582
	  	13-Oct-2010	  	15-Nov-2001
 10109698.4
	  		 		  	Pending	  	HARATS Dror; BLOOM Nira


  
 39 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 52630
	  	Hong Kong
 DIV
	  	17-Nov-2000
 60/248,582
	  	2-Dec-2011	  	15-Nov-2001
 11113094.5
	  		  	3182.034HK21	  	Pending	  	HARATS Dror; BLOOM Nira
	 26026
	  	Israel
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 155940
	  	30-Mar-2009
 155940
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26027
	  	India
 NP
	  	17-Nov-2000
 60/248,582
	  	14-May-2003	  	15-Nov-2001
 743/CHENP/2003
	  	20-Nov-2007
 211599
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26028
	  	USA
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 10/416,917
	  		  		  	Abandoned	  	HARATS Dror
	 26029
	  	Canada
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 2,429,342
	  		  		  	Pending	  	HARATS Dror; BLOOM Nira
	 26030
	  	Australia
 NP
	  	17-Nov-2000
 60/248,582
	  	15-May-2003	  	15-Nov-2001
 2002224002
	  	26-Jul-2007
 2002224002
	  		  	Abandoned	  	HARATS Dror
	 28653
	  	Australia
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Dec-2004	  	15-Nov-2001
 2003222427
	  	09-Sep-2010
 2003222427
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 49098
	  	Australia
 DIV
	  	15-Nov-2001
 2002224002
	  	25-Jun-2010	  	15-Nov-2001
 2010202660
	  	1-Dec 2011
 2010202660
	  		  	Granted	  	HARATS Dror; BREITBART
Eyal; BLOOM Nira
	 26031
	  	Japan
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 2002-543626
	  	16-Jan-2009
 4,243,653
	  		  	Granted	  	HARATS Dror; BLOOM Nira
	 26032
	  	China
 NP
	  	17-Nov-2000
 60/248,582
	  	16-Jul-2003	  	15-Nov-2001
 01822075.4
	  	04-Feb-2009
 ZL0182275.4
	  		  	Granted	  	HARATS Dror; BLOOM Nira


  
 40 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










															
	 26033
	  	Republic of Korea
 NP
	  	17-Nov-2000
 60/248,582
	  	17-May-2003	  	15-Nov-2001
 2003-7006728
	  	14-Nov-2008
 869814
	  	Granted	  	HARATS Dror
	 44105
	  	Republic of Korea
 DIV
	  	17-Nov-2000
 60/248,582
	  	28-Jul-2008	  	15-Nov-2001
 2008-7018598
	  	10-Sep-2009
 917854
	  	Granted	  	HARATS Dror;  BLOOM Nira
	 26034
	  	Mexico
 NP
	  	17-Nov-2000
 60/248,582
	  	16-May-2003	  	15-Nov-2001
 PA/a/2003/004325
	  	15-Aug-2008
 259670
	  	Granted	  	HARATS Dror

 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS 

 

																	
	 Our Ref
	  	 Country
	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 28918
	  	 USA
 CIP
	  	04-Oct-1998
 126447
	  		  	17-Nov-2004
 10/989,724
	  		  		  	Abandoned	  	HARATS Dror; SHOENFELD Yehuda; GEORGE Jacob; YACOV Niva

 COMPOSITIONS CONTAINING BETA 2-GLYCOPROTEIN I FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISEASE 

 

																	
	 Our Ref
	  	 Country
	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	 Inventor

	 30236
	  	PCT	  	17-Nov-2004
 10/989,724
	  		  	25-Sep-2005
 IL2005/001022
	  	Publ. Date:
 26-May-2006

Publ. #: |WO2006/054281
	  		  	Expired	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

	 39233
	  	 Europe
 NP
	  	17-Nov-2004
 10/989,724
	  	13-Jun-2007	  	25-Sep-2005
 05788473.6
	  		  		  	Abandoned	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva

	 42004
	  	 Hong Kong
 NP
	  	17-Nov-2004
 10/989,724
	  		  	12-Sep-2007
 07109873.6
	  		  		  	Abandoned	  	 HARATS Dror;
 SHOENFELD Yehuda;

GEORGE Jacob; YACOV Niva



  
 41 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 PROMOTERS EXHIBITING ENDOTHELIAL CELL SPECIFICITY AND METHODS OF USING SAME FOR REGULATION OF ANGIOGENESIS

  

																	
	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 28376
	  	USA
 CIP
	  	17-Nov-2000
 60/248,582
	  		  	14-Nov-2004
 10/988,487
	  	6-Dec 2011
 8,071,740
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50225
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	01-Feb-2011	  	14-Nov-2004
 13/018,447
	  	26-June 2012
 8,206,743
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50927
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	02-May-2011	  	14-Nov-2004
 13/098,512
	  		  		  	Aban	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 47407
	  	USA
 DIV
	  	17-Nov-2000
 60/248,582
	  	13-Nov-2009	  	14-Nov-2004
 12/591,252
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 60001
	  	USA
 Con
	  	17-Nov-2000
 60/248,582
	  	13-July 2012	  	14-Nov-2004
 13/549,355
	  		  	3182.0370004	  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 30269
	  	PCT	  	14-Nov-2004	  		  	14-Nov-2005	  	Publ. Date: 18-May-2006	  		  	Expired	  	HARATS Dror;
GREENBERGER Shoshana


  
 42 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










															
		  		  	10/988,487	  		  	IL2005/001195	  	Publ. #: WO2006/051545	 		  	
	 [* * *]
	  		  		  		  		  		 		  	
	 [* * *]
	  		  		  		  		  		 		  	
	 47087
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	28-Aug-2009	  	14-Nov-2005
 09168899.4
	  	2 Nov 2011
 2174668
	 	Grnated	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49224
	  	Hong Kong
 DIV
	  		  	12-Oct-2010	  	14-Nov-2005
 10109638.7
	  	15 June 2012
 HK1143078
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49804
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	01-Oct-2010	  	14-Nov-2005
 EP10185195.4
	  	26 Sep 2012
 2301586
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 49805
	  	Europe
 DIV
	  	14-Nov-2004
 10/988,487
	  	30-Sep-2010	  	14-Nov-2005
 EP10184033.8
	  		 	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39318
	  	Australia
 NP
	  	14-Nov-2004
 10/988,487
	  	08-Jun-2007	  	14-Nov-2005
 2005303385
	  		 	Allowed	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 51825
	  	Australia
 DIV
	  	14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	28 June 2012
 2011205076
	 	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 53691
	  	Australia	  	14-Nov-2004	  	15 June 2012	  	14-Nov-2005	  		 	Pending	  	HARATS Dror;
GREENBERGER Shoshana;


  
 43 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










															
		  	DIV	  	10/988,487	  		  	2012203578	  		  		  	BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39323
	  	New Zealand
 NP
	  	14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	14-Nov-2005
 555612
	  	08-Apr-2010
 555612
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 47297
	  	New Zealand
 DIV
	  	14-Nov-2004
 10/988,487
	  	09-Oct-2009	  	14-Nov-2005
 580289
	  	05-Apr-2011
 580289
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39324
	  	South Africa
 NP
	  	14-Nov-2004
 10/988,487
	  	05-Jun-2007	  	14-Nov-2005
 2007/04687
	  	31-Dec-2008
 2007/04687
	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  	
	 50629
	  	Singapore
 DIV
	  	14-Nov-2004
 10/988,487
	  	11-Apr-2011	  	14-Nov-2005
 201102612-7
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 39315
	  	Israel
 NP
	  	14-Nov-2004
 10/988,487
	  	14-May-2007	  	14-Nov-2005
 183187
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 50104
	  	Israel
 DIV
	  	14-Nov-2004
 10/988,487
	  	31-Oct-2010	  	14-Nov-2005
 209034
	  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  	


  
 44 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 39317
	  	Canada
 NP
	  	14-Nov-2004
 10/988,487
	  	17-May-2007	  	14-Nov-2005
 2,587,469
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39319
	  	Japan
 NP
	  	14-Nov-2004
 10/988,487
	  	14-May-2007	  	14-Nov-2005
 2007-540833
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 52137
	  	Japan
 Div
	  	14-Nov-2004
 10/988,487
	  	Sep 2011	  	14-Nov-2005
 2011-191492
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39320
	  	China
 NP
	  	14-Nov-2004
 10/988,487
	  	13-Aug-2007	  	14-Nov-2005
 200580046412.8
	  		  		  	Aban	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39321
	  	Republic
 of KoreaNP
	  	14-Nov-2004
 10/988,487
	  	14-Jun-2007	  	14-Nov-2005
 2007-7013464
	  		  		  	Pending	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat; PELED Michael
	 39322
	  	Mexico
 NP
	  	14-Nov-2004
 10/988,487
	  	11-May-2007	  	14-Nov-2005
 MX/a/2007/005783
	  	8 May 2012
 299008
	  		  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 52598
	  	Mexico
 Div
	  	14-Nov-2004
 10/988,487
	  		  	14-Nov-2005	  	4 Sep 2012
 303042
	  	3182.037MX11	  	Granted	  	HARATS Dror;
GREENBERGER Shoshana;
BREITBART Eyal; BANGIO
Livnat
	 [* * *]
	  		  		  		  		  		  		  		  	


  
 45 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 Method for treating vascular inflammation and psoriasis

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 Treatment Of Inflammation
  

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	
	 [* * *]
	  		  		  		  		  		  		  		  	
	 53305
	  	PCT	  	12 Dec 2011
 61/569,545 and
 12 Dec
2011
 61/569,481
	  		  	11 Dec 2012
 PCT/US2012/068995
	  		  	3182.014PC01	  	Pending	  	MENDEL, Itzhak;
 FEIGE, Erez;
 YACOV, Niva;

PROPHETE-MEIRAN, Oshrat;
BREITBART, Eyal;

SALEM, Yaniv



  
 46 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










																	
	 Treatment Methods Using Adenovirus

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 [* * *]
	  		  		  		  		  		  		  		  	

  

																	
	 TARGETED GENE EXPRESSION USING PREPROENDOTHELIN-1 PROMOTERS

 

	 Our
Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	  	SKGF Ref	  	Status	  	Inventor
	 N/A
	  	USA CIP	  	03-Mar-1994
 08/254,015
	  		  	28-Feb-1995
 08395742
	  	05-May-1998
 5747340
	  	Originally assinged to Syntex
USA. Licensed to VBL	  	Granted	  	HARATS Dror;
 KURIHARA Hiroki;

NANETTE BELLONI Paula; SIGAL
Charles Elliott


  

																	
	 METHOD AND COMPOSITION TO INCREASE RADIATION-INDUCED TUMOR THERAPEUTIC EFFECTS

 

	 Our Ref
	  	Country	  	Earliest Priority	  	Entry Date	  	Filing Date
Application No.	  	Issue Date
Patent No.	 	 SKGF Ref
	  	Status	  	Inventor
	 N/A
	  	PCT	  	08-Dec-2009
 61/283,696
	  		  	07-Dec-2010
 US2010/059204
	  	Publ. Date: 16-Jun-2011

Publ. #: WO/2011/071859
	 	As of June 2012, the applicant is also VBL	  	Pending	  	KOLESNICK, Richard, N.
 STANCEVIC, Branka;

SADELAIN, Michel;
 FUKS, Zvi;

VARDA-BLOOM, Nira;
 HARATS, Dror;



  
 47 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










															
	 Trademark: VBL therapeutics & logo

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 47638
	  	Europe	 	5, 42 & 44	  		  	03-Dec-2009
 008730541
	  	02-Jun-2010
 008730541
	  		  	Registered
	  
 Trademark: VASCULAR BIOGENICS

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42092
	  	Israel	 	42	  		  	23-Aug-2007
 203346
	  	06-May-2009
 203346
	  		  	Registered
	 43074
	  	USA
 (Paris)
	 	42	  	23-Aug-2007
 203346
	  	14-Feb-2008
 77/397,305
	  	22-Jun-2010
 3,805,239
	  		  	Registered
	 43075
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203346
	  	18-Feb-2008
 006675599
	  	20-Feb-2009
 006675599
	  		  	Registered


  
 48 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 Trademark: VBL VASCULAR BIOGENICS LTD. & Device 

 

															
	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42199
	  	Israel	 	42	  		  	09-Sep-2007
 203748
	  	10-May-2009
 203748
	  		  	Registered
	 43602
	  	USA
 (Paris)
	 	42	  	09-Sep-2007
 203748
	  	03-Mar-2008
 77/411,204
	  	22-Jun-2010
 3,805,245
	  		  	Registered
	 43603
	  	Europe
 (Paris)
	 	42	  	09-Sep-2007
 203748
	  	04-Mar-2008
 006721823
	  	04-Sep-2009
 006721823
	  		  	Registered
	  
 Trademark: VTS

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42198
	  	Israel	 	5	  		  	09-Sep-2007
 203747
	  	06-May-2009
 203747
	  		  	Registered
	 43600
	  	USA
 (Paris)
	 	5	  	09-Sep-2007
 203747
	  	03-Mar-2008
 77/411,151
	  	20-Oct-2009
 3,697,519
	  		  	Registered
	 43601
	  	Europe
 (Paris)
	 	5	  	09-Sep-2007
 203747
	  	04-Mar-2008
 006721484
	  	20-Feb-2009
 006721484
	  		  	Registered


  
 49 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 Trademark: VASCULAR TARGETING SYSTEM VTS 

 

															
	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 41864
	  	Israel	 	5	  		  	23-Aug-2007
 203345
	  	08-Sep-2009
 203345
	  		  	Registered
	 43072
	  	USA
 (Paris)
	 	5	  	23-Aug-2007
 203345
	  	14-Feb-2008
 77/397,328
	  	18-May-2010
 3,789,108
	  		  	Registered
	 43073
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203345
	  	18-Feb-2008
 006675896
	  	29-Jan-2009
 006675896
	  		  	Registered


  
 50 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].










															
	 Trademark: VBL
  

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 42093
	  	Israel	 	42	  		  	23-Aug-2007
 203347
	  	22-Jan-2009
 203347
	  		  	Registered
	 43076
	  	USA
 (Paris)
	 	42	  	23-Aug-2007
 203347
	  	14-Feb-2008
 77/397,293
	  	14-Jul-2009
 3,653,176
	  		  	Registered
	 43077
	  	Europe
 (Paris)
	 	5, 42 & 44	  	23-Aug-2007
 203347
	  	18-Feb-2008
 006673263
	  	22-Jan-2009
 006673263
	  		  	Registered
	  
 Trademark: VBL therapeutics & logo

 

	 Our Ref

Client Ref
	  	Country	 	Class	  	Earliest
Priority	  	Filing Date
Application No.	  	Registration Date
Registration No.	  	SKGF Ref	  	Status
	 47612
	  	Israel	 	42	  		  	30-Nov-2009
 225329
	  	07-Feb-2011
 225329
	  		  	Registered
	 47639
	  	USA
 (Paris)
	 	42	  	30-Nov-2009
 225329
	  	26-Apr-2010
 85/023,397
	  	24-May-2011
 3,964,829
	  		  	Registered


  
 51 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].









 Domains: VBL 

vascularbiogenics.com 
 vascularbiogenicsltd.com 

vbl-therapeutics.com 
 vbltherapeutics.com 

vbltx.com 
 vascularbiogenics.net 

vbl.co.il 
 vblrx.com 

vascular-biogenics.com 

  
 52 

 

	
	Portions of this exhibit have been omitted and filed separately with the SEC pursuant to a confidential treatment request and are indicated by [* * *].